The role of radionuclide imaging in heart failure

Area of Science:

• Cardiovascular Medicine
• Nuclear Cardiology
• Medical Imaging

Background:

• Heart failure (HF) incidence and mortality are rising, uniquely worsening within cardiovascular disease over 25 years.
• Accurate diagnosis and risk stratification are critical for effective HF management.
• Distinguishing ischemic from non-ischemic cardiomyopathy is vital for treatment decisions, particularly revascularization.

Purpose of the Study:

• To review the role of radionuclide imaging in heart failure (HF).
• To assess nuclear imaging's value in differentiating ischemic vs. non-ischemic etiologies.
• To evaluate its utility in risk stratification and guiding treatment strategies, including cardiac neuronal imaging.

Main Methods:

• Review of studies on radionuclide imaging in heart failure.
• Focus on Single Photon Emission Computed Tomography (SPECT) for coronary artery disease detection.
• Emphasis on meta-iodobenzylguanidine (mIBG) imaging for cardiac sympathetic function assessment.

Main Results:

• SPECT demonstrates high sensitivity and negative predictive value for detecting coronary artery disease in HF patients.
• SPECT aids in establishing treatment strategies for HF, including new-onset congestive heart failure (CHF).
• Cardiac mIBG imaging is valuable for risk stratification and monitoring therapeutic response in HF patients.

Conclusions:

• Radionuclide imaging, particularly SPECT and mIBG, plays a significant role in HF management.
• Nuclear imaging aids in etiological diagnosis, risk stratification, and guiding personalized treatment strategies.
• mIBG imaging offers prognostic information and can monitor treatment efficacy in heart failure.